Unknown

Dataset Information

0

A time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) activity.

ABSTRACT: A novel time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) was developed. We used a straightforward strategy to modify a known ALK substrate into a peptide biosensor that can accommodate terbium luminescence sensitization upon its phosphorylation by ALK. Since this strategy is generalizable, this high-throughput screening compatible assay serves as an example for development of other kinase assays that employ terbium luminescence as a read-out.

SUBMITTER: Cui W 

PROVIDER: S-EPMC4288484 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) activity.

Cui Wei W   Parker Laurie L LL  

Chemical communications (Cambridge, England) 20141118 2

A novel time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) was developed. We used a straightforward strategy to modify a known ALK substrate into a peptide biosensor that can accommodate terbium luminescence sensitization upon its phosphorylation by ALK. Since this strategy is generalizable, this high-throughput screening compatible assay serves as an example for development of other kinase assays that employ terbium luminescence as a read-out. ...[more]

Similar Datasets

Unknown Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).
| S-EPMC6294449 | biostudies-other
Unknown Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.
| S-EPMC6625372 | biostudies-literature
Unknown Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
| S-EPMC2941277 | biostudies-other
Unknown Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
| S-EPMC8271116 | biostudies-literature
Unknown Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
| S-EPMC5924614 | biostudies-literature
Unknown From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).
| S-EPMC5664077 | biostudies-literature
Unknown Time-resolved luminescence detection of spleen tyrosine kinase activity through terbium sensitization.
| S-EPMC3632334 | biostudies-literature
Unknown ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
| S-EPMC4395299 | biostudies-literature
Unknown Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.
| S-EPMC6274813 | biostudies-literature
Unknown Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.
| S-EPMC4324543 | biostudies-literature